Treatment of Acetaminophen Toxicity With N-acetylcysteine

Treatment of Acetaminophen Toxicity With Intravenous vs Oral N-acetylcysteine: A Retrospective Review

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00725179

Enrollment

130

Registered

2008-07-30

Start date

2008-08-31

Completion date

2008-10-31

Last updated

2011-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acetaminophen Toxicity

Keywords

acetaminophen toxicity, n-acetylcysteine, liver toxicity

Brief summary

Retrospective chart review of patients who received N-acetylcysteine for APAP toxicity to assess length of oral vs IV treatment and overall healthcare costs.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Admitted to CHMCA between June 1, 2004 to May 31, 2008 with a qualifying ICD-9 diagnosis code for the following APAP overdose situations; poisoning, accidental, suicide attempt, therapeutic use, assault, and undetermined (965.4, E850.4, E950.0, E935.4, E962.0, E980.0) * Serum APAP concentrations ≥ 150 g/mL at 4 hours or a serum concentration above the possible hepatotoxic line on the Rumack-Matthew's nomogram if obtained \> 4 hours post ingestion * Between the ages of 0-21 years

Exclusion criteria

* Serum APAP concentrations are not actually documented * Patient did not receive oral or IV NAC treatment * Patient has a preexisting liver disease such as cirrhosis or hepatitis C * Patient \> 21 years of age

Design outcomes

Primary

Measure	Time frame
Duration of oral vs IV NAC treatment in hours	From admission to discharge

Secondary

Measure	Time frame
Overall healthcare costs associated with IV vs Oral NAC treatment	From admission to discharge

Countries

United States

Outcome results